As of Jun 29
| -0.05 / -1.23%|
The 4 analysts offering 12-month price forecasts for AcelRx Pharmaceuticals Inc have a median target of 4.00, with a high estimate of 7.00 and a low estimate of 3.50. The median estimate represents a 0.00% increase from the last price of 4.00.
The current consensus among 5 polled investment analysts is to Hold stock in AcelRx Pharmaceuticals Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.